Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Active, not recruiting · NCT03047135 · Registry updated 2026-05-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis | Prostate | Active, not recruiting | Phase 2 | 2026-05-12 | NCT03047135 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Allegheny Cancer Center | Pittsburgh | United States | 4 |
| Johns Hopkins Hospital | Baltimore | United States | 10 |
| Thomas Jefferson University | Philadelphia | United States | 165 |
| University of Nebraska Medical Center | Omaha | United States | 397 |